Author

J. Koblinski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Organism:mouse· 2

Frequent Co-Authors

B. Hu· 4 shared A. C. Faber· 2 shared K. V. Floros· 2 shared M. G. Dozmorov· 2 shared M. Shende· 2 shared A. Banito· 1 shared A. Jose· 1 shared A. K. Yu· 1 shared

Activity by Year

2022-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

B. Hu

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma

K. V. Floros, C. K. Fairchild, J. Li, K. Zhang, J. L. Roberts, R. Kurupi, B. Hu, V. Kraskauskiene, N. Hosseini, S. Shen, M. M. Inge, K. Smith-Fry, L. Li, A. Sotiriou, K. M. Dalton, , A. C. Faber

This study shows that inhibiting SUMOylation with TAK-981 stabilizes cBAF complexes and disrupts the SS18::SSX-driven transcriptome in synovial sarcoma, leading to tumor inhibition.

bioRxiv · Apr 25, 2024 · PreprintCancer Biology

Inhibition of LATS Kinases in Ovarian Cancer Activates Cyclin D1/CDK4 and Decreases DYRK1A Activity

F. Sesay, S. Saini, A. Pajimola, A. Witt, B. Hu, J. Koblinski, L. Litovchick

This study shows that inhibiting LATS kinases in ovarian cancer cells activates cyclin D1/CDK4 and reduces DYRK1A activity, promoting tumor growth.

bioRxiv · Dec 6, 2022 · PreprintCancer Biology

Limitations of Busulfan to Create Humanize Mice with an Innate Immune System.

O. Alhawiti, B. Hu, J. Koblinski, C. Guo, J. W. LANDRY

This study evaluates busulfan's effectiveness in preconditioning humanized mice for immune cell engraftment, finding it works well for hIL15-Tg-NSG but not SGM3-NSG mice.

bioRxiv · Jul 15, 2022 · PreprintImmunology

Genomic screening reveals UBA1 as a potent and druggable target in c-MYC-high TNBC models

S. Jacob, T. H. Turner, J. Cai, K. V. Floros, A. K. Yu, C. M. Coon, R. Khatri, M. A. Alzubi, C. T. Jakubik, Y. M. Bouck, M. Puchalapalli, M. Shende, M. G. Dozmorov, S. Boikos, B. Hu, , A. C. Faber

The paper identifies UBA1 as a druggable target in c-MYC-high TNBC models, showing TAK-243 induces ER-stress and apoptosis in vitro and in vivo.

bioRxiv · May 17, 2022Cancer Biology